TMCnet News
"Penny Stocks that Perform" pick is: CLWR, COIN, MMDA, OSIP, STEM(M2 PressWIRE Via Acquire Media NewsEdge) Pennyperformers.com "Penny Stocks that Perform" picks are: Clearwire Corporation (NASDAQ: CLWR), Converted Organics Inc. (NASDAQ: COIN), Mega Media Group, Inc., (OTCBB: MMDA), OSI Pharmaceuticals, Inc. (NASDAQ: OSIP), StemCells, Inc. (NASDAQ: STEM)...and Proudly Introducing Proprietary Push Technology (PPT). The Newest and Revolutionary Technology for Increasing Investor Visability. REAL Awareness for REAL Companies. Click below for a full demonstration. http://newmediaadvisors.info/newmedia.swf Sign-up for our FREE Stock Alerts AND NEWSLETTER at www.pennyperformers.com May 14, 2009 -- Clearwire Corporation (NASDAQ: CLWR), a provider of high-speed wireless broadband services, and network technologies company Cisco (Nasdaq:CSCO) have announced an alliance designed to enhance and expand CLEAR 4G mobile WiMAX services throughout the US. Under the terms of the agreement, Clearwire has selected Cisco as its national Internet Protocol Next-Generation Network (IP NGN) core infrastructure provider and Cisco has announced plans to build new mobile WiMAX devices for the CLEAR 4G mobile WiMAX service for the consumer, small office or home office (SOHO) and small and medium-sized business (SMB) markets. According to the company, as part of a multiyear network build-out plan with Cisco, the CLEAR 4G mobile WiMAX service is to be available in major US metropolitan areas. The company's open all-IP network, combined with significant spectrum holdings, provides substantive network capacity to deliver next-generation broadband access. In addition, Cisco is aiming to introduce its first mobile WiMAX device later in 2009. Clearwire has selected and is in the process of testing and certification of a Cisco IP NGN architecture that includes Cisco 7600 Series Internet routers, Cisco ONS 15454 and Cisco ONS 15310 platforms, Cisco ASA Firewalls and the Cisco Service and Application Module for IP (SAMI) Home Agent. The Cisco 7600 Series Routers are high-performance, intelligent routers designed for deployment at the network edge where performance, IP-enabled services, redundancy and fault resiliency are key requirements. Future Cisco converged WiMAX and Wi-Fi enabled devices are to include products from Linksys by Cisco line of consumer routers. The company will also look to expand its WiMAX portfolio with the growth of the CLEAR 4G network across the US. The two companies will jointly develop and implement go-to-market plans that will benefit from Cisco's distribution channels and presence with consumers and businesses, which will assist to enhance and expand CLEAR mobile WiMAX services throughout the US, the company said. The two companies also recently announced their involvement in forming the WiMAX Innovation Network for developers, which will initially cover over 20 square miles in Silicon Valley. Cisco will provide core Internet Protocol Next-Generation Network (IP NGN) core infrastructure equipment in support of the WiMAX Innovation Network. Service is expected to be available to developers by late summer 2009. Service will be provided free to a limited number of qualified developers for one year. Clearwire will provide WiMAX USB Modems for USD49.99. May 15, 2009 -- Converted Organics Inc. (NASDAQ: COIN) announced today that it has been named as the Lead Technology Partner of the World Sports Alliance (WSA) International Business Consortium (WSAIBC) For the Joint Development of the WSA Public-Private partnership Programs in the Specific Sector of Waste-to-Fertilizer (WTF). The World Sports Alliance is an intergovernmental organization (IGO) created through a private initiative in support of the United Nations Millennium Project and its Development Goals. The WSA is headquartered at the UN Plaza in New York City and has 24 member states. "The selection of our technology by the WSA is a very positive development for Converted Organics. The first Member State of the WSA in the program has proposed the delivery of 10 individual fertilizer production units at a price of $2.25 million per unit. We have selected Control & Power Systems, Inc.(CPS) of Fairfield, NJ to design, engineer, and fabricate the small scale units for the first proposal from the WSA," said Jack Walsdorf, Vice President of Converted Organics for Waste Management. "The overseas market for this type of equipment is exciting. Our relationship with the WSA will highlight our technology to all 24 Member States of the WSA and other groups who are made aware of COIN thru the WSA program," said Jack Walsdorf. About Converted Organics Inc. Converted Organics, based in Boston, MA, is dedicated to producing high-quality, all-natural, organic soil amendment and fertilizer products through food waste recycling. The Company uses its proprietary High Temperature Liquid Composting (HTLC) system, a proven, state-of-the-art microbial digestion technology, to process various biodegradable food wastes into dry pellet and liquid concentrate organic fertilizers that help grow healthier food and improve environmental quality. Converted Organics sells and distributes its environmentally-friendly fertilizer products in the retail, professional turf management, and agribusiness markets. May 14, 2009 -- Mega Media Group, Inc., (OTCBB: MMDA) announced that Pulse87 has been named the Official Radio Partner of the NYC Pride 2009. Pulse87 will be the exclusive radio partner involved with all the week's festivities to include The Rapture on the River on Saturday, June 27th, "The March" on Sunday, June 28th, Pridefest on Sunday, June 28th and culminating at the Dance on the Pier on Sunday, June 28th. The event attracts more than 2.5 Million revelers from all over the world for a weekend of celebration for the men and women who fought and still fight for gay rights. Heritage of Pride, Inc. Managing Director Todd Emmett added, "This is a new era. We want to be associated with open-minded and forward-thinking organizations such as Pulse87. We aren't afraid of delivering our messages of acceptance and unity and Pulse87 isn't afraid to play the dance music we love and this city yearns for." Val Portela, Pulse87's Marketing / Promotions Director, commented, "This is an amazing accomplishment for a radio station that is just over a year old. Having been able to achieve this alliance is something I'm really proud of. The organization is a powerful one and their members are one of our strongest audiences. We are proud to have brought back dance music to New York; a genre that is positive, uplifting and a staple in this proud community." Commenting on the announcement, Alex Shvarts, CEO of Mega Media Group, stated, "We are extremely excited and honored to be the Official Radio Partner of an event with such a longstanding history in NYC. The challenges we have faced as a station true to our music are continually assured by the continuing support of the local organizations and events that are the fabric of New York. Having our brand in front of over 2.5 Million consumers celebrating their community is incredible and we thank Heritage of Pride, Inc. for the opportunity." About Heritage of Pride Heritage of Pride is wholly volunteer-managed non-partisan, tax-exempt, not-for-profit corporation that organizes Lesbian, Gay, Bisexual and Transgendered Pride events in New York City to commemorate and celebrate the Stonewall riots. These Events are organized for and on behalf of all lesbian, gay, bisexual and transgender individuals and groups, and all others who support the struggle for the liberation of these communities. In the spirit of Stonewall, Heritage of Pride welcomes the participation of all, regardless of age, creed, gender, gender identification, HIV status, national origin, physical, mental or developmental ability, race, religion or sexual origin. About Mega Media Group Mega Media Group, Inc. is a multimedia entertainment holding company with several subsidiaries that offer a broad range of services. May 15, 2009 -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today preliminary data from two Phase I dose escalation studies of oral OSI-906, a small molecule insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors. The studies, along with a third on-going Phase I trial assessing OSI-906 in combination with Tarceva, comprise part of the Company's principal oncology development program targeting the IGF-1R. The program also includes translational research and biomarker development activities around this highly attractive oncology target. In an intermittent oral dosing study, OSI-906 was well-tolerated up to doses of 450mg and has provided preliminary evidence of anti-tumor activity, with one confirmed partial response in an adrenocortical carcinoma (ACC) patient; one minor response in a patient with non-small cell lung cancer (NSCLC); 14 patients with stabilization of their disease for longer than 12 weeks including 7 patients with stabilization of their disease for longer than 24 weeks (out of 27 patients evaluable for tumor response to date). In a continuous dosing study, OSI-906 also had an acceptable safety profile and disease stabilization for longer than 12 weeks has been observed in 8 out of 29 patients evaluable for tumor response to date. Both Phase I studies continue to accrue patients at higher doses to determine the maximum tolerated dose (MTD) for both intermittent and continuous dosing of OSI-906, and to establish a recommended dose and dosing schedule for a Phase II clinical trial of OSI-906. "We believe these data, along with early data from an additional combination Phase I study with Tarceva, continue to position OSI-906 as a potential first-in-class small molecule inhibitor of the IGF-1R," stated Colin Goddard, Ph.D., Chief Executive Officer of OSI Pharmaceuticals. "Our extensive research around this crucial oncology signaling target has led us to develop a comprehensive development effort that includes targeting tumors such as ACC and ovarian cancer, where IGF-2 over-expression could indicate a particular dependence on this signaling pathway, and also NSCLC, where our understanding of EMT and compensatory signaling mechanism suggest that a Tarceva/OSI-906 combination could be particularly effective. With continued progress in our program we believe we could begin two registration-oriented trials - a monotherapy study in ACC in 2009 and a Tarceva combination study in NSCLC in 2010." The OSI-906 Phase I single-agent data will be presented in two poster presentations at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, FL on May 30, 2009 between 8 a.m. and noon EDT (Abstracts #3544 and #2559). Study Results Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small molecule insulin like growth factor -1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumors- C.P. Carden, et al. (Abstract #3544) The primary objective of this study (OSI-906-102) is to determine the maximum tolerated dose (MTD) and recommended Phase II dose of oral OSI-906 for three intermittent dosing schedules: Schedule 1: days 1-3, every 14 days; Schedule 2: days 1-5, every 14 days; Schedule 3: days 1-7, every 14 days. Secondary objectives include safety profile, pharmacokinetics (PK) and pharmacodynamics (PD) profiles and preliminary anti-tumor activity. Preliminary results from 33 patients evaluable to date showed that OSI-906 was well-tolerated up to doses of 450mg, with no dose limiting toxicities (DLTs) and no grade 3 or 4 toxicities reported to date. Most common adverse events were grade 1 rash, diarrhea, fatigue and peripheral edema. Frequency and severity of toxicities did not correlate with dose level. Two cases of hyperglycemia (one grade 1; one grade 2) were reported. Encouraging anti-tumor activity was seen in the study, with one partial response in an ACC patient at the 450mg dose (in the Schedule 1 group), 14 patients with stable disease for greater-than or equal to 12 weeks including 7 patients with stable disease for greater-than or equal to 24 weeks. Of particular note, anti-tumor activity was seen in two ACC patients and one NSCLC patient: -- One 2nd-line ACC patient, a 35-year old woman with metastatic disease, had a partial response (PR) confirmed at 16 weeks of treatment with OSI-906. No drug-related toxicities have been observed to date and this patient continues on therapy. -- One 4th-line NSCLC patient, a 77-year old man with metastatic disease, had a minor response per the treating physician and a best response (per RECIST) of stable disease for 43 weeks. -- One 3rd-line ACC patient had stable disease for 30 weeks. The study authors also note that PK is dose-proportional up to 450mg. An exploratory analysis from glucose monitoring also indicates that significant hyperglycemia was not observed in patients in spite of hyperinsulinemia at higher doses. The MTD in this study has not yet been reached and patient accrual is on-going. Phase I dose escalation study of continuous oral dosing of OSI-906, an insulin like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors- C.R. Lindsay, et al. (Abstract #2559) The primary objective of this study (OSI-906-101) is to determine the MTD and recommended Phase II dose of oral OSI-906 administered either once daily or twice daily. Secondary objectives also included safety profile, PK and PD profiles and preliminary anti-tumor activity. Preliminary results from 37 patients with advanced solid tumors (9 colorectal, 6 pancreatic, 3 renal, 3 esophageal and 16 other tumor types) also show that continuous oral dosing of OSI-906, given either once or twice a day, has an acceptable safety profile. One recent DLT of asymptomatic grade 3 hyperglycemia was reported at the 450mg once-a-day dose, however, this patient was asymptomatic and glucose returned to normal by Day 2, and no dose interruptions or reductions were necessary. OSI-906 plasma concentrations exceed concentration required for anti-tumor efficacy in preclinical models, with twice-a-day dosing providing improved coverage above threshold. Further, PD target modulation and disease stabilization were observed. While no objective tumor responses have been reported to date, 8 patients had stable disease greater-than or equal to 12 weeks including 4 patients who had stable disease greater-than or equal to 24 weeks. The MTD in this study has not yet been reached and patient accrual is on-going. Additional Background on OSI-906 IGF-1 and IGF-2 are growth factors, or hormones, known to stimulate growth and survival of cancerous cells. IGF-1R has been viewed as an important therapeutic target due to its involvement in the growth and proliferation of a variety of human cancers, including colorectal, prostate, non-small cell lung, breast and ovarian cancers. In preclinical studies, OSI-906 blocked the ability of IGF-1R to signal in xenograft mouse models of human colorectal cancer. Preclinical research also showed that colon cancer tumor cells respond to OSI-906 because they produce and are dependent on the growth-promoting effects of IGF-2. In addition to colorectal cancer, OSI-906 has also been shown to inhibit growth of human pancreatic and thyroid cancers in animal models. The IGF/IGF-1R signaling pathway has also been implicated in protecting tumor cells from apoptosis induced by a number of cytotoxic agents as well as molecular targeted therapies including EGFR inhibitors. Preclinical data also suggest that OSI-906 may be synergistic with Tarceva in non-small cell lung and pancreatic human tumor xenografts. About OSI Pharmaceuticals OSI Pharmaceuticals is committed to "shaping medicine and changing lives" by discovering, developing and commercializing high-quality, novel and differentiated targeted medicines designed to extend life and improve the quality of life for patients with cancer and diabetes/obesity. May 15, 2009 -- StemCells, Inc. (NASDAQ: STEM) announced today that the U.S. Patent and Trademark Office (PTO) has upheld the validity of the remaining two neural stem cell patents which were subjected to reexamination proceedings commenced by Neuralstem, Inc. The upheld patents are the subject of two related lawsuits initiated by StemCells against Neuralstem, which allege infringement of a total of six patents. These six patents collectively claim the manufacture and use of human neural stem and progenitor cells as tools for drug discovery and as therapeutic agents. The PTO's decision to uphold the two patents is final and cannot be appealed. Consequently, StemCells is asking the federal district court in Maryland to resume the infringement lawsuits against Neuralstem. "The PTO's latest action is a reaffirmation of the validity of the patents asserted against Neuralstem. Each of our reexamined patents has now been twice tested and twice granted by the Patent Office," said Martin McGlynn, President and CEO of StemCells, Inc. "We now look forward to our day in court. Litigation can be a slow and meticulous process, but we plan to ensure that those who wish to commercialize neural stem cells for drug discovery or therapeutic uses, recognize the validity and value of our patents." The two most recently upheld patents are U.S. Patent Number 6,294,346 and U.S. Patent Number 7,101,709, which claim, respectively, methods for using neural stem and progenitor cells for the screening of drugs and biological agents. In its latest communications, the PTO has issued Notices of Intent to Issue Ex Parte Reexamination Certificates for both the '346 and '709 patents. During the reexamination proceedings, the Company submitted minor amendments to certain, but not all, of the claims. With these notices of allowance, the PTO has affirmed all of the previously issued claims, as amended, and so all of the reexaminations initiated by Neuralstem have been resolved to StemCells' satisfaction. There are a total of 173 patent claims going forward from the six patents involved in the two suits against Neuralstem. More About the Litigation Against Neuralstem StemCells initiated its first lawsuit against Neuralstem in July 2006 in federal court in Maryland, alleging that Neuralstem's activities violate claims in four patents exclusively licensed to StemCells. In late 2006, Neuralstem petitioned the PTO to reexamine two of the patents in the case, namely U.S. Patent No. 6,294,346 (claiming the use of human neural stem cells for drug screening) and U.S. Patent No. 7,101,709 (claiming the use of human neural stem cells for screening biological agents). Then, in April 2007, Neuralstem petitioned the PTO to reexamine the remaining two patents in the case, namely U.S. Patent No. 5,851,832 (claiming methods for proliferating human neural stem cells) and U.S. Patent No. 6,497,872 (claiming methods for transplanting human neural stem cells). In June 2007, the Company agreed to a voluntary stay of the first lawsuit while the reexamination proceedings were ongoing. In April 2008, the PTO reaffirmed the '832 and '872 patents. In May 2008, StemCells filed a second patent infringement lawsuit in federal court in Northern California against both Neuralstem and its two founders, alleging that Neuralstem's activities infringe claims in two additional patents exclusively licensed to the Company, specifically U.S. Patent No. 7,361,505 (claiming composition of matter of human neural stem cells derived from any source material) and U.S. Patent No. 7,115,418 (claiming methods for proliferating human neural stem cells). In addition, the second suit alleges various state law causes of action against Neuralstem arising out of its repeated derogatory statements to the public about our patent portfolio. In July 2008, the California court denied Neuralstem's motion to dismiss the second lawsuit and then, in August 2008, it transferred the suit to Maryland for resolution. About StemCells, Inc. StemCells, Inc. is a clinical-stage biotechnology company focused on the research, development and commercialization of products derived from stem and progenitor cell technologies. In its therapeutic product development programs, StemCells is focused on developing cell-based therapeutics to treat diseases of the central nervous system and liver. StemCells has pioneered the discovery and development of HuCNS-SC(R) cells, its highly purified, expandable population of human neural stem cells. StemCells has completed a six patient Phase I clinical trial of its proprietary HuCNS-SC product candidate as a treatment for neuronal ceroid lipofuscinosis (NCL), a rare and fatal neurodegenerative disease that affects infants and young children. StemCells has also received approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial of the HuCNS-SC cells to treat Pelizaeus-Merzbacher Disease (PMD), a rare and fatal brain disorder that mainly affects young children. StemCells is also pursuing applications of its cell technologies to develop research tools, such as cell-based assays, media and reagent tools, which the Company believes represent nearer-term commercial opportunities. StemCells has exclusive rights to approximately 55 issued or allowed U.S. patents and approximately 200 granted or allowed non-U.S. patents. About PennyPerformers.com PennyPerformers.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies. Penny Performers email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Penny Performers Report home page at www.PennyPerformers.com and select the "join now" button. Join us at www.PennyPerformers.com for a complimentary subscription to the most exciting online financial newsletter on the market. Disclaimer: Verify all claims and do your own due diligence. PennyPerformers.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyPerformers.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. PennyPerformers.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), PennyPerformers.com is owned and operated by PennyPerformers.com. Neither PennyPerformers.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since PennyPerformers.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in PennyPerformers.com statements and opinions and such statements and opinions cannot be considered independent. PennyPerformers.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. PennyPerformers.com services are often paid for using free-trading shares. PennyPerformers.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration. Visit us for a full Disclaimer at: www.PennyPerformers.com/disclaimer.htm ((Comments on this story may be sent to [email protected])) (c) 2009 M2 COMMUNICATIONS |